An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...
A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced ...
A groundbreaking gene-editing therapy developed by Eli Lilly and Verve Therapeutics reduced "bad" LDL cholesterol by up to 62 ...
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol ...
For millions of people at high risk of heart disease, keeping cholesterol under control remains a lifelong struggle. Now, a major medical breakthrough has raised hopes: a single infusion that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results